This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Medtronic's (MDT) STROKE AF Trial Outcome Backs ICM Progress
by Zacks Equity Research
STROKE AF trial shows Medtronic's (MDT) Reveal LINQ ICM has a seven-fold advantage in detecting AF compared to traditional standard of care in patients with large vessel or small vessel stroke.
Medtronic (MDT) Progresses in Neuromodulation on New FDA Nod
by Zacks Equity Research
Medtronic's (MDT) SenSight claims to deliver patient-specific DBS therapy for the treatment of symptoms associated with Parkinson's, dystonia and essential tremor and medically refractory epilepsy.
Abbott (ABT) Confirms Capacity to Support MCS Devices Demand
by Zacks Equity Research
Abbott's (ABT) HeartMate 3 heart pump can significantly enhance quality of life and reduce adverse events.
The Zacks Analyst Blog Highlights: United Parcel Service, Medtronic, Shopify, Square and U.S. Bancorp
by Zacks Equity Research
The Zacks Analyst Blog Highlights: United Parcel Service, Medtronic, Shopify, Square and U.S. Bancorp
Top Stock Reports for United Parcel Service, Medtronic & Shopify
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including United Parcel Service, Inc. (UPS), Medtronic plc (MDT) and Shopify Inc. (SHOP).
Medtronic (MDT) Diabetes Arm Secures Two Approvals in Europe
by Zacks Equity Research
These two latest innovations are likely to enable Medtronic (MDT) to offer the only pump that adjusts and corrects every five minutes with an infusion set that lasts twice as long.
Medtronic's (MDT) Q4 Earnings Beat Estimates, Margins Up
by Zacks Equity Research
Medtronic's (MDT) fourth-quarter results reflect a strong recovery in terms of elective procedures.
Medtronic (MDT) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Medtronic (MDT) delivered earnings and revenue surprises of 5.63% and 0.55%, respectively, for the quarter ended April 2021. Do the numbers hold clues to what lies ahead for the stock?
Share Gain in Core Markets to Aid Medtronic (MDT) Q4 Earnings
by Zacks Equity Research
Growing momentum in capital equipment purchases might have aided Medtronic (MDT) Q4 earnings.
3 Stocks to Watch on Rising Demand for Smart Medical Devices
by Kaustav Ghosh
Rising demand for smart medical devices due to their convenience of providing active monitoring of patients makes it wise to look at names like Apple (AAPL), Garmin (GRMN) and Medtronic (MDT).
Medtronic (MDT) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Medtronic (MDT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Medtronic (MDT) Reveals Promising Results From Evolut Trial
by Zacks Equity Research
The Low Risk Trial has demonstrated non-inferiority of Medtronic's (MDT) TAVR system over open heart surgery.
Medtronic's (MDT) Coronary Market Share Grows Amid Pandemic
by Zacks Equity Research
In Gastrointestinal, Medtronic (MDT) is witnessing some modest share gains, driven in part by its partnership with the NHS in England.
The Zacks Analyst Blog Highlights: Mastercard, Home Depot, Disney, Netflix and Medtronic
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Mastercard, Home Depot, Disney, Netflix and Medtronic
Top Stock Reports for Mastercard, Home Depot & Walt Disney
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including Mastercard Incorporated (MA), The Home Depot, Inc. (HD), and The Walt Disney Company (DIS).
Medtronic (MDT) to Enhance Patient Care via Digital Portal
by Zacks Equity Research
Medtronic's (MDT) first patient-centric digital health platform is expected to provide better outcome for patients undergoing the company's SCS therapy.
United Therapeutics (UTHR) Q1 Earnings Miss, Sales Beat
by Zacks Equity Research
United Therapeutics (UTHR) reports mixed first-quarter 2021 results. Higher sales of Orenitram, Unituxin and Tyvaso offset lower sales of Remodulin and Adcirca.
The Zacks Analyst Blog Highlights: Netflix, Medtronic, Stryker, Sysco and EOG Resources
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Netflix, Medtronic, Stryker, Sysco and EOG Resources
Top Stock Reports for Netflix, Medtronic & Stryker
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Netflix (NFLX), Medtronic (MDT), and Stryker (SYK).
Integra (IART) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
Integra (IART) is optimistic about maintaining its strength in its international business, along with its portfolio optimization strategy.
Medtronic (MDT) Boosts Diabetes Management via New Infusion Set
by Zacks Equity Research
Medtronic's (MDT) recently introduced Medtronic Extended infusion set with longer wearability enhances convenience and comfort, thus improving diabetes care.
Medtronic's (MDT) GI Genius Module Gets FDA De Novo Clearance
by Zacks Equity Research
Medtronic's (MDT) GI Genius Module is the only commercially available computer-aided detection system which uses artificial intelligence to identify colorectal polyploid.
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Thermo Fisher, T-Mobile, Medtronic and Square
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Thermo Fisher, T-Mobile, Medtronic and Square
Top Analyst Reports for Berkshire Hathaway, Thermo Fisher & T-Mobile
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway (BRK.B), Thermo Fisher (TMO), and T-Mobile (TMUS).
Medtronic (MDT) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
Medtronic's (MDT) ventilator sales are robust and prospects of the Diabetes arm remain strong amid the pandemic.